ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 139,36
-0,71%
Dow Jones
42 579,08
-0,99%
DAX
23 141,03
-1,31%
Brent Oil
70,255
1,32%
Bitcoin
88 851,63
-1,20%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Solid Biosciences Inc (SLDB)

  7. Solid Biosciences Inc (SLDB) Actualités

SLDB

Solid Biosciences (SLDB)

Solid Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SLDB
DateHeureSourceTitreSymboleSociété
06/03/202523h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLDBSolid Biosciences Inc
06/03/202522h35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLDBSolid Biosciences Inc
06/03/202522h16GlobeNewswire Inc.Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesNASDAQ:SLDBSolid Biosciences Inc
05/03/202514h00GlobeNewswire Inc.Solid Biosciences to Participate at Upcoming Investor ConferencesNASDAQ:SLDBSolid Biosciences Inc
04/03/202522h07GlobeNewswire Inc.Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLDBSolid Biosciences Inc
25/02/202522h05Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLDBSolid Biosciences Inc
22/02/202500h04Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:SLDBSolid Biosciences Inc
18/02/202522h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLDBSolid Biosciences Inc
18/02/202522h47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLDBSolid Biosciences Inc
18/02/202522h35Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:SLDBSolid Biosciences Inc
18/02/202522h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLDBSolid Biosciences Inc
18/02/202513h00GlobeNewswire Inc.Solid Biosciences Announces Pricing of Underwritten OfferingNASDAQ:SLDBSolid Biosciences Inc
18/02/202512h45GlobeNewswire Inc.Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003NASDAQ:SLDBSolid Biosciences Inc
14/02/202523h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SLDBSolid Biosciences Inc
12/02/202522h30Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLDBSolid Biosciences Inc
21/01/202514h30GlobeNewswire Inc.Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s AtaxiaNASDAQ:SLDBSolid Biosciences Inc
15/01/202522h05GlobeNewswire Inc.Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic MedicinesNASDAQ:SLDBSolid Biosciences Inc
08/01/202522h05GlobeNewswire Inc.Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
07/01/202522h15GlobeNewswire Inc.Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s AtaxiaNASDAQ:SLDBSolid Biosciences Inc
23/12/202422h05GlobeNewswire Inc.Solid Biosciences Added to the Nasdaq Biotechnology IndexNASDAQ:SLDBSolid Biosciences Inc
04/12/202414h00GlobeNewswire Inc.Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene TherapiesNASDAQ:SLDBSolid Biosciences Inc
14/11/202418h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLDBSolid Biosciences Inc
14/11/202414h00GlobeNewswire Inc.Solid Biosciences to Present at the Jefferies London Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
12/11/202422h58Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLDBSolid Biosciences Inc
06/11/202422h05GlobeNewswire Inc.Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:SLDBSolid Biosciences Inc
06/11/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLDBSolid Biosciences Inc
31/10/202413h00GlobeNewswire Inc.Solid Biosciences to Participate at the Truist Securities BioPharma SymposiumNASDAQ:SLDBSolid Biosciences Inc
23/09/202414h00GlobeNewswire Inc.Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines ConferenceNASDAQ:SLDBSolid Biosciences Inc
12/09/202414h00GlobeNewswire Inc.Solid Biosciences to Participate at the 2024 Cantor Global Healthcare ConferenceNASDAQ:SLDBSolid Biosciences Inc
13/08/202422h08GlobeNewswire Inc.Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:SLDBSolid Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SLDB

Dernières Valeurs Consultées

LSE
59NZ
Akademiska 38
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces